BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30842365)

  • 1. The roles and role-players in thyroid cancer angiogenesis.
    Rajabi S; Dehghan MH; Dastmalchi R; Jalali Mashayekhi F; Salami S; Hedayati M
    Endocr J; 2019 Apr; 66(4):277-293. PubMed ID: 30842365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
    Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
    Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription Factor Prospero Homeobox 1 (PROX1) as a Potential Angiogenic Regulator of Follicular Thyroid Cancer Dissemination.
    Rudzińska M; Mikula M; Arczewska KD; Gajda E; Sabalińska S; Stępień T; Ostrowski J; Czarnocka B
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis in endocrine tumors.
    Turner HE; Harris AL; Melmed S; Wass JA
    Endocr Rev; 2003 Oct; 24(5):600-32. PubMed ID: 14570746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of angiogenesis in the pathogenesis of cancer.
    Hoff PM; Machado KK
    Cancer Treat Rev; 2012 Nov; 38(7):825-33. PubMed ID: 22677191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the micronutrient iodine in thyroid carcinoma angiogenesis.
    Daniell K; Nucera C
    Aging (Albany NY); 2016 Dec; 8(12):3180-3184. PubMed ID: 27997357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-deficiency-induced long lasting angiogenic reaction in thyroid cancers occurs via a vascular endothelial growth factor-hypoxia inducible factor-1-dependent, but not a reactive oxygen species-dependent, pathway.
    Gérard AC; Humblet K; Wilvers C; Poncin S; Derradji H; de Ville de Goyet C; Abou-el-Ardat K; Baatout S; Sonveaux P; Denef JF; Colin IM
    Thyroid; 2012 Jul; 22(7):699-708. PubMed ID: 22663304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis in the thyroid gland.
    Ramsden JD
    J Endocrinol; 2000 Sep; 166(3):475-80. PubMed ID: 11029748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
    Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
    Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.
    Jebreel A; England J; Bedford K; Murphy J; Karsai L; Atkin S
    Int J Exp Pathol; 2007 Aug; 88(4):271-7. PubMed ID: 17696908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo.
    Zhang H; Yang L; Teng X; Liu Z; Liu C; Zhang L; Liu Z
    Tumour Biol; 2016 Feb; 37(2):2415-23. PubMed ID: 26383519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis and prostate cancer tumor growth.
    Nicholson B; Theodorescu D
    J Cell Biochem; 2004 Jan; 91(1):125-50. PubMed ID: 14689586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
    Bender RJ; Mac Gabhann F
    BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications.
    Harper J; Moses MA
    EXS; 2006; (96):223-68. PubMed ID: 16383021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad targeting of angiogenesis for cancer prevention and therapy.
    Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
    Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis and acute myeloid leukemia.
    Haouas H
    Hematology; 2014 Sep; 19(6):311-23. PubMed ID: 24192539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
    Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
    Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.